OSLO, Norway, Dec. 12, 2019 /PRNewswire/ -- Nordic Nanovector
ASA (OSE: NANO) reports an update on its LYMRIT 37-05 Phase 1 trial
of Betalutin® in patients with relapsed/refractory diffuse large
B-cell lymphoma (R/R DLBCL) who are not eligible for autologous
stem cell transplantation (SCT). DLBCL is an aggressive form of
non-Hodgkin's lymphoma (NHL) and accounts for up to 43% of all
cases, making it the most common type of NHL.
This open-label, dose-escalation safety trial is designed to
assess the safety, tolerability, pharmacokinetic profile and
preliminary anti-tumour activity of Betalutin® in up to 24
patients. The primary goal of the trial is to identify the
maximally tolerated dose of Betalutin® which will then be further
evaluated for safety and anti-tumour activity in an expansion
cohort in order to select the recommended dose for phase
2. Three additional patients are currently being enrolled for
further evaluation of the final dose cohort as one patient has
experienced a reversible DLT (dose limiting toxicity).
On the three completed cohorts, no safety issues were
identified. Evidence of disease control has been noted in some of
the enrolled patients. We expect to complete the data read-out for
the dose-escalation phase and submit the data to an international
congress in 1H 2020.
Eduardo Bravo, Nordic
Nanovector's Chief Executive Officer, commented: "Patients with
relapsed/refractory DLBCL who are not eligible for stem cell
transplantation have very limited treatment options and a poor
prognosis. As the safety profile of Betalutin® will guide its
potential for combination regimens as well as single agent
consolidation therapy, we look forward to completing this part of
the trial and proceeding with the expansion cohort."
For further information, please contact:
IR enquiries
Malene Brondberg
VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
Media Enquiries
Mark
Swallow/David Dible (Citigate
Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®,
a novel CD37-targeting radioimmunotherapy designed to advance the
treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication
with substantial unmet medical need, representing a growing market
forecast to be worth nearly USD 29
billion by 2026. Nordic Nanovector intends to retain
marketing rights and to actively participate in the
commercialisation of Betalutin® in core markets.
Further information can be found at
www.nordicnanovector.com.
Forward-looking statements
This press release contains certain forward-looking
statements. These statements are based on management's
current expectations and are subject to uncertainty and changes in
circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their
nature, will have an impact on Nordic Nanovector's business,
financial condition and results of operations. The terms
"anticipates", "assumes", "believes", "can", "could", "estimates",
"expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case,
their negative, or other variations or comparable terminology are
used to identify forward-looking statements. These forward-looking
statements are not historic facts. There are a number of factors
that could cause actual results and developments to differ
materially from those expressed or implied in the forward-looking
statements. Factors that could cause these differences include, but
are not limited to, risks associated with implementation of Nordic
Nanovector's strategy, risks and uncertainties associated with the
development and/or approval of Nordic Nanovector's product
candidates, ongoing and future clinical trials and expected trial
results, the ability to commercialise Betalutin®, technology
changes and new products in Nordic Nanovector's potential market
and industry, Nordic Nanovector's freedom to operate (competitors
patents) in respect of the products it develops, the ability to
develop new products and enhance existing products, the impact of
competition, changes in general economy and industry conditions,
and legislative, regulatory and political factors. No assurance can
be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
This information is subject to a duty of disclosure pursuant
to Sections 4-2 and 5-12 of the Securities Trading Act.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-provides-update-on-lymrit-37-05-phase-1-dlbcl-trial,c2988281